Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-cash Items (2022 - 2024)

BioNexus Gene Lab's Non-cash Items history spans 3 years, with the latest figure at -$508330.0 for Q4 2024.

  • For Q4 2024, Non-cash Items rose 36.06% year-over-year to -$508330.0; the TTM value through Dec 2024 reached -$2.3 million, down 21.1%, while the annual FY2024 figure was -$2.3 million, 21.1% down from the prior year.
  • Non-cash Items for Q4 2024 was -$508330.0 at BioNexus Gene Lab, up from -$1.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $40263.0 in Q1 2022 and bottomed at -$1.5 million in Q3 2024.
  • The 3-year median for Non-cash Items is -$88513.0 (2023), against an average of -$391636.8.
  • The largest annual shift saw Non-cash Items tumbled 44889.89% in 2023 before it skyrocketed 56.66% in 2024.
  • A 3-year view of Non-cash Items shows it stood at $2246.0 in 2022, then tumbled by 35494.88% to -$794969.0 in 2023, then surged by 36.06% to -$508330.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Non-cash Items are -$508330.0 (Q4 2024), -$1.5 million (Q3 2024), and -$344207.0 (Q2 2024).